CAR Therapy Expands Beyond Cancer Treatment

Got story updates? Submit your updates here. ›

A new review outlines how chimeric antigen receptor (CAR) therapy is rapidly evolving beyond traditional CAR-T cells, with researchers exploring a wider family of engineered cell platforms including NK cells, γδ T cells, NKT cells, MAIT cells, DNT cells, Tregs, macrophages, dendritic cells, neutrophils, and stem-cell-based systems. Each platform offers different strengths in safety, tissue penetration, persistence, and manufacturing, potentially extending CAR-based therapy from cancer into autoimmune, infectious, fibrotic, and senescence-related disorders.

Why it matters

While CAR-T therapy has transformed treatment for some blood cancers, it still faces limitations in solid tumors and serious toxicity concerns. Diversifying the CAR technology into different engineered cell types could help overcome these barriers, make cell therapy more precise and scalable, and expand its applications beyond oncology into a range of other diseases.

The details

The review, published in Precision Clinical Medicine, outlines how CAR technology is rapidly evolving beyond traditional CAR-T cells. While αβ CAR-T cells remain the field's benchmark, with high response rates in blood cancers, they also bring major limitations like cytokine release syndrome, neurotoxicity, weak solid-tumor performance, and high manufacturing costs. Researchers are now exploring alternative CAR platforms that offer different strengths - for example, CAR-NK cells for rapid killing and lower toxicity risks, CAR-γδ T cells for natural tumor tropism and allogeneic potential, and CAR-macrophages for solid tumors and fibrosis due to their tissue-penetrating abilities.

• The review was published on March 13, 2026.

What’s next

The authors caution that most alternative CAR platforms remain early in development and will require disease-specific evaluation and long-term safety monitoring before they can reshape routine care.